Major depressive disorder (MDD) is a leading cause of disability worldwide, affecting an estimated 5% of adults globally and up to 8.3% of adults in the United States. Alarmingly, depression is a major contributor to suicide and self-harm, and the treatment gap remains significant-up to 79% of those affected in some regions do not receive adequate care Discover the latest research, treatment advances, and expert insights in our dedicated journal.

Obesity has reached epidemic proportions, with more than one billion people worldwide now living with obesity-nearly 880 million adults and 159 million children and adolescents as of 2022. The prevalence of obesity has more than tripled since 1975, and by 2030, the number of adults living with obesity is projected to surpass 1.13 billion. Discover the insights on latest treatment trends and many more through our journal.

Type 1 diabetes is an autoimmune condition in which the body’s immune system destroys insulin-producing cells in the pancreas, requiring lifelong insulin therapy. With the global number of cases projected to rise to as many as 17.4 million by 2040, our journals provide essential updates on breakthroughs in treatment and management for those living with type 1 diabetes.

Ulcerative colitis is a chronic inflammatory disease of the colon, affecting approximately 1% of the US population-about 1.9 million people-and with a prevalence ranging from 156 to 291 cases per 100,000 globally. While mortality rates are generally low, the condition often leads to substantial morbidity and long-term health challenges. Explore the latest findings and therapeutic breakthroughs in our ulcerative colitis journal.